PMID- 30718670
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20200818
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Feb 4
TI  - Spatially Controlled Surface Modification of Porous Silicon for Sustained Drug 
      Delivery Applications.
PG  - 1367
LID - 10.1038/s41598-018-37750-w [doi]
LID - 1367
AB  - A new and facile approach to selectively functionalize the internal and external 
      surfaces of porous silicon (pSi) for drug delivery applications is reported. To 
      provide a surface that is suitable for sustained drug release of the hydrophobic 
      cancer chemotherapy drug camptothecin (CPT), the internal surfaces of pSi films 
      were first modified with 1-dodecene. To further modify the external surface of 
      the pSi samples, an interlayer was applied by silanization with 
      (3-aminopropyl)triethoxysilane (APTES) following air plasma treatment. In 
      addition, copolymers of N-(2-hydroxypropyl) acrylamide (HPAm) and N-benzophenone 
      acrylamide (BPAm) were grafted onto the external pSi surfaces by spin-coating and 
      UV crosslinking. Each modification step was verified using attenuated total 
      reflection-Fourier transform infrared (ATR-FTIR) spectroscopy, water contact 
      angle (WCA) measurements, X-ray photoelectron spectroscopy (XPS) and scanning 
      electron microscopy (SEM). In order to confirm that the air plasma treatment and 
      silanization step only occurred on the top surface of pSi samples, confocal 
      microscopy was employed after fluorescein isothiocyanate (FITC) conjugation. Drug 
      release studies carried out over 17 h in PBS demonstrated that the modified pSi 
      reservoirs released CPT continuously, while showing excellent stability. 
      Furthermore, protein adsorption and cell attachment studies demonstrated the 
      ability of the graft polymer layer to reduce both significantly. In combination 
      with the biocompatible pSi substrate material, the facile modification strategy 
      described in this study provides access to new multifunctional drug delivery 
      systems (DDS) for applications in cancer therapy.
FAU - Zhang, De-Xiang
AU  - Zhang DX
AD  - Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical 
      Sciences, Monash University, Parkville, Victoria, 3052, Australia.
AD  - Commonwealth Scientific and Industrial Research Organisation (CSIRO) 
      Manufacturing, Clayton, Victoria, 3168, Australia.
FAU - Yoshikawa, Chiaki
AU  - Yoshikawa C
AD  - Commonwealth Scientific and Industrial Research Organisation (CSIRO) 
      Manufacturing, Clayton, Victoria, 3168, Australia.
AD  - International Centre for Materials Nanoarchitectonics, National Institute for 
      Materials Science, 1-2-1, Sengen, Tsukuba, Ibaraki, 305-0047, Japan.
FAU - Welch, Nicholas G
AU  - Welch NG
AUID- ORCID: 0000-0001-8172-8252
AD  - Commonwealth Scientific and Industrial Research Organisation (CSIRO) 
      Manufacturing, Clayton, Victoria, 3168, Australia.
FAU - Pasic, Paul
AU  - Pasic P
AD  - Commonwealth Scientific and Industrial Research Organisation (CSIRO) 
      Manufacturing, Clayton, Victoria, 3168, Australia.
FAU - Thissen, Helmut
AU  - Thissen H
AD  - Commonwealth Scientific and Industrial Research Organisation (CSIRO) 
      Manufacturing, Clayton, Victoria, 3168, Australia. helmut.thissen@csiro.au.
FAU - Voelcker, Nicolas H
AU  - Voelcker NH
AUID- ORCID: 0000-0002-1536-7804
AD  - Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical 
      Sciences, Monash University, Parkville, Victoria, 3052, Australia. 
      nicolas.voelcker@monash.edu.
AD  - Commonwealth Scientific and Industrial Research Organisation (CSIRO) 
      Manufacturing, Clayton, Victoria, 3168, Australia. nicolas.voelcker@monash.edu.
AD  - Melbourne Centre for Nanofabrication, Victorian Node of Australian National 
      Fabrication Facility, Clayton, Victoria, 3168, Australia. 
      nicolas.voelcker@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190204
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Fibronectins)
RN  - 444W947O8O (Europium)
RN  - XT3Z54Z28A (Camptothecin)
RN  - Z4152N8IUI (Silicon)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Adsorption
MH  - Camptothecin/pharmacology
MH  - Cell Adhesion
MH  - Cell Count
MH  - Drug Delivery Systems/*methods
MH  - Drug Liberation
MH  - Europium/chemistry
MH  - Fibronectins/chemistry
MH  - Humans
MH  - Kinetics
MH  - Photoelectron Spectroscopy
MH  - Porosity
MH  - Serum Albumin, Human/chemistry
MH  - Silicon/*chemistry
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Surface Properties
PMC - PMC6361965
COIS- The authors declare no competing interests.
EDAT- 2019/02/06 06:00
MHDA- 2020/08/19 06:00
PMCR- 2019/02/04
CRDT- 2019/02/06 06:00
PHST- 2018/07/27 00:00 [received]
PHST- 2018/12/06 00:00 [accepted]
PHST- 2019/02/06 06:00 [entrez]
PHST- 2019/02/06 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2019/02/04 00:00 [pmc-release]
AID - 10.1038/s41598-018-37750-w [pii]
AID - 37750 [pii]
AID - 10.1038/s41598-018-37750-w [doi]
PST - epublish
SO  - Sci Rep. 2019 Feb 4;9(1):1367. doi: 10.1038/s41598-018-37750-w.